@article{bab0e096569f44ef88ca3f19a422c56f,
title = "Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared with the General Population",
abstract = "Background: Previous studies of cardiovascular disease (CVD) among HIV-infected individuals have been limited by the inability to validate and differentiate atherosclerotic type 1 myocardial infarctions (T1MIs) from other events. We sought to define the incidence of T1MIs and risk attributable to traditional and HIV-specific factors among participants in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) and compare adjusted incidence rates (IRs) to the general population Atherosclerosis Risk in Communities (ARIC) cohort. Methods: We ascertained and adjudicated incident MIs among individuals enrolled in 7 NA-ACCORD cohorts between 1995 and 2014. We calculated IRs, adjusted incidence rate ratios (aIRRs), and 95% confidence intervals of risk factors for T1MI using Poisson regression. We compared aIRRs of T1MIs in NA-ACCORD with those from ARIC. Results: Among 29,169 HIV-infected individuals, the IR for T1MIs was 2.57 (2.30 to 2.86) per 1000 person-years, and the aIRR was significantly higher compared with participants in ARIC [1.30 (1.09 to 1.56)]. In multivariable analysis restricted to HIV-infected individuals and including traditional CVD risk factors, the rate of T1MI increased with decreasing CD4 count [≥500 cells/μL: ref; 350-499 cells/μL: aIRR = 1.32 (0.98 to 1.77); 200-349 cells/μL: aIRR = 1.37 (1.01 to 1.86); 100-199 cells/μL: aIRR = 1.60 (1.09 to 2.34); <100 cells/μL: aIRR = 2.19 (1.44 to 3.33)]. Risk associated with detectable HIV RNA [<400 copies/mL: ref; ≥400 copies/mL: aIRR = 1.36 (1.06 to 1.75)] was significantly increased only when CD4 was excluded. Conclusions: The higher incidence of T1MI in HIV-infected individuals and increased risk associated with lower CD4 count and detectable HIV RNA suggest that early suppressive antiretroviral treatment and aggressive management of traditional CVD risk factors are necessary to maximally reduce MI risk.",
keywords = "HIV, cardiovascular disease, myocardial infarction",
author = "Drozd, {Daniel R.} and Kitahata, {Mari M.} and Althoff, {Keri N.} and Jinbing Zhang and Gange, {Stephen J.} and Sonia Napravnik and Burkholder, {Greer A.} and Mathews, {William C.} and Silverberg, {Michael J.} and Sterling, {Timothy R.} and Heckbert, {Susan R.} and Budoff, {Matthew J.} and {Van Rompaey}, Stephen and Delaney, {Joseph A.C.} and Cherise Wong and Weiqun Tong and Palella, {Frank J.} and Elion, {Richard A.} and Martin, {Jeffrey N.} and Brooks, {John T.} and Jacobson, {Lisa P.} and Eron, {Joseph J.} and Justice, {Amy C.} and Freiberg, {Matthew S.} and Klein, {Daniel B.} and Post, {Wendy S.} and Saag, {Michael S.} and Moore, {Richard D.} and Crane, {Heidi M.}",
note = "Funding Information: Supported by the National Institutes of Health (Grants U01-AI069918, U01-AA013566, U24-AA020794, U01-AA020790, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-AI69432, U01-AI69434, U01-HD32632, U10-EY08057, U10-EY08052, U10-EY08067, UL1-RR024131, UL1-TR000083, U54-MD007587, F31-DA035713, G12-MD007583, KL2-TR000421, K01-AI070001, K01-AI071754, K01-AI093197, K23 EY013707, K24-00432, MO1-RR-00052, N02-CP55504, P30-AI027763, P30-AI094189, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, P30-AI036219, P30-MH62246, R01-CA165937, R01-AA16893, R01-DA11602, R01-DA04334, R01-DA12568, R24-AI067039, R56-AI102622, R56-HL 126538, R01-HL 126538, Z01-CP010214, R01-DA026770, and Z01-CP010176 from the National Institutes of Health, USA); contract CDC200-2006-18797 from the Centers for Disease Control and Prevention, USA; contract 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health Resources and Services Administration, USA; grants TGF-96118, HCP-97105, CBR-86906, and CBR-94036 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long Term Care; and the Government of Alberta, Canada. Publisher Copyright: {\textcopyright} Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2017",
month = aug,
day = "15",
doi = "10.1097/QAI.0000000000001450",
language = "English (US)",
volume = "75",
pages = "568--576",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",
}